Richard Kaplan

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Tuberculosis Incidence Rates during 8 Years of Follow-Up of an Antiretroviral Treatment Cohort in South Africa: Comparison with Rates in the Community

Ankur Gupta‐Wright, Robin Wood, Richard Kaplan et al. · PLoS ONE · 2012 · 247 citations · Full text

Public Health, Community Health, Infectious Diseases +17

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

Michael Aboud, Richard Kaplan, Johannes Lombaard et al. · The Lancet Infectious Diseases · 2019 · 198 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial

Chloe Orkin, Kathleen Squires, Jean‐Michel Molina et al. · Clinical Infectious Diseases · 2018 · 168 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Conservation of First-Line Antiretroviral Treatment Regimen where Therapeutic Options are Limited

Catherine Orrell, Guy Harling, Stephen D Lawn et al. · Antiviral Therapy · 2007 · 145 citations · Full text

Public Health, Infectious Diseases, Pharmacotherapy +16